glpg0974
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01496937)
Timeline
Indications
Mechanism of action
- Free fatty acid receptor 2ANTAGONIST
FFAR2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(((r)-1-(benzo(b)thiophene-3-carbonyl)-2-methyl-azetidine-2-carbonyl)-(3-chloro-benzyl)-amino)-butyric acid
- glpg0974
- glpg0974
- glpg0974
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01829321 | Phase 2 | Apr 1, 2013 | Galapagos NV |
| NCT01721980 | Phase 1 | Oct 1, 2012 | Galapagos NV |
| NCT01496937 | Phase 1 | Dec 1, 2011 | Galapagos NV, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 3 | 3 | 2 | 2011 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1